The biotech finance sector remains in retroactive mode, with money reaching shareholders and companies through corporate mergers and deals rather than through venture capital or public market financing.
8 billion, Merck paid an 81% premium for Prometheus Bioscience and its anti-inflammatory assets. Meanwhile, the quarter’s top venture round went to ElevateBio, a gene therapy platforms provider, with a series D round that brought another $401 million to the substantial venture capital stack raised by the company since 2019.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: